FATE is focusing FT500 on non-small-cell lung carcinoma (NSCLC) with stable disease in 4/8 monotherapy and 2/3 CPI combo patients initially and data for its FT516 candidate in AML and B-cell lymphoma could be released in December. Fate Therapeutics (FATE) Fate Therapeutics is at the forefront of the cellular immunotherapy space, with it taking healthy donor cells, which are then modified ex vivo using pharmacologic modulators, to improve the cells’ biological properties and therapeutic function. As per the terms of the agreement, FATE will be paid $50 million in cash up front and receive a $50 million equity investment.